Lastly, rearrangements involving KMT2A, MECOM and NUP98 are added as genetic abnormalities that are acceptable to diagnose AML with <20% blasts; however, no specific blast cut-off requirement is specified. This evidence concerns the gene MECOM and acute myeloid leukemia.